RECRUITING

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients. The results of this study will be the basis for future studies exploring this area.

Official Title

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Quick Facts

Study Start:2015-03
Study Completion:2025-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02393703

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All patients ≥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors, without an invasive component; or other benign pancreatic disease will be eligible.
  1. * The presence of metastatic disease or disease that precludes resection
  2. * Receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months of being enrolled in the study
  3. * INR \>2
  4. * Known clotting factor deficiency or hypercoagulable state
  5. * Any patient with the need or anticipated need for full anti-coagulation during hospitalization for the resection.
  6. * Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to resection.
  7. * IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion for invasive component Additionally, if at the discretion of the operating surgeon, blood collection would lead to undue morbidity, the patient will be excluded and replaced

Contacts and Locations

Study Contact

William Jarnagin, MD
CONTACT
212-639-7601
Peter Kingham, MD
CONTACT
212-639-5260

Principal Investigator

William Jarnagin, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • William Jarnagin, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2015-03
Study Completion Date2025-03

Study Record Updates

Study Start Date2015-03
Study Completion Date2025-03

Terms related to this study

Keywords Provided by Researchers

  • exosomes
  • 15-015

Additional Relevant MeSH Terms

  • Pancreatic Cancer
  • Benign Pancreatic Disease